- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03472950
Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis
June 12, 2019 updated by: Jeffrey Statland, University of Kansas Medical Center
The purpose of this research study is to evaluate the safety and effectiveness of Ranolazine, and how well it is tolerated in patients with Amyotrophic Lateral Sclerosis (ALS).
Ranolazine is an FDA approved drug that is used for decreasing chest pain.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Amyotrophic Lateral Sclerosis (ALS) is a progressive debilitating and fatal neurodegenerative disease involving the motor neurons in the primary motor cortex, corticospinal tracts, brainstem and spinal cord with 5,000 newly diagnosed patients per year in the USA.
There is a pressing need for additional therapies, as the only two FDA-approved drugs for ALS, riluzole and edaravone, showed prolongation of median survival of only two to three months and only a modest benefit in daily functioning, respectively.
The ability to identify FDA approved drugs which can be repurposed to ALS, and which may slow disease progression, alleviate symptoms, or prolong survival will have an immediate positive impact of the lives of patients with ALS and their family members.
Hypothesis: Ranolazine, an FDA approved drug for angina which inhibits the late Na+ current and intracellular Ca2+ accumulation may be neuroprotective in ALS by reducing neuronal hyperexcitability, may slow disease progression and reduce cramp frequency.
Study Type
Interventional
Enrollment (Anticipated)
20
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Sherri Anderson
- Phone Number: 913-945-9936
- Email: sanderson10@kumc.edu
Study Locations
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- Recruiting
- University of Kansas Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with clinically definite, probable, laboratory supported probable, or possible ALS per revised El Escorial criteria
- Cramp frequency greater than 4 cramps per week during 2 week run in
- ALS functional rating scale-revised (ALSFRS-R) score of greater than 24
- Able to lie on back for study procedures
Exclusion Criteria:
- Tracheostomy invasive ventilation, or use of non-invasive ventilation greater than 12 hours per day
- Pregnant or lactating
- Participation in a prior experimental drug trial less than 30 days prior to screening
- Patients taking ranolazine
- Patients taking medications which are contraindicated for use with ranolazine such as strong CYP3 inhibitors (ketoconazole, clarithromycin, nelfinavir), and CYP3 inducers (rifampin, phenobarbital)
- Patients with clinically significant medical comorbidities (hepatic, renal, cardiac, etc)
- Patients with baseline QT interval prolongation on Electrocardiography (ECG)
- Patients pre-disposed to secondary QT prolongation for other health conditions like family history of congenital long QT syndrome, heart failure, bradycardia, or cardiomyopathies
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SEQUENTIAL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Ranolazine 500mg
Participants will take Ranolazine 500mg twice daily for up to 4 weeks.
|
Ranolazine is an FDA approved drug for angina (ongoing chest pain or pressure that is felt when the heart does not get enough oxygen).
|
EXPERIMENTAL: Ranolazine 1000mg
Participants will take Ranolazine 1000mg twice daily for up to 4 weeks.
|
Ranolazine is an FDA approved drug for angina (ongoing chest pain or pressure that is felt when the heart does not get enough oxygen).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose limiting toxicities (DLT)
Time Frame: Up to Week 12
|
Measured as any drug-related serious adverse event, or drug-related adverse event necessitating study withdrawal.
If a dose has less than 33% DLTs it will be considered tolerable.
|
Up to Week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cramp Questionnaire
Time Frame: Baseline, Weeks 2, 6, and 8
|
The cramp questionnaire asks if a person has experienced cramps in last week, how many total, whether they occur daily, how long they last on average (seconds - minutes), locations (body region).
Responses measure average severity on a scale from 1-9.
A score of 1 being mild and score of 9 being worst ever experienced.
|
Baseline, Weeks 2, 6, and 8
|
Fasciculation frequency on muscle ultrasound
Time Frame: Baseline, Weeks 2 and 6
|
Count of fasciculation frequency in bilateral biceps, tibialis anterior, and gastrocnemius over 30 seconds
|
Baseline, Weeks 2 and 6
|
Cramp potential duration
Time Frame: Baseline, Weeks 2 and 6
|
Abductor hallucis brevis measured on EMG after supramaximal stimulation of posterior tibial nerve at 2 and 5 Hz
|
Baseline, Weeks 2 and 6
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
June 11, 2018
Primary Completion (ANTICIPATED)
October 1, 2019
Study Completion (ANTICIPATED)
November 1, 2019
Study Registration Dates
First Submitted
March 1, 2018
First Submitted That Met QC Criteria
March 14, 2018
First Posted (ACTUAL)
March 21, 2018
Study Record Updates
Last Update Posted (ACTUAL)
June 13, 2019
Last Update Submitted That Met QC Criteria
June 12, 2019
Last Verified
June 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neuromuscular Diseases
- Neurodegenerative Diseases
- Spinal Cord Diseases
- TDP-43 Proteinopathies
- Proteostasis Deficiencies
- Motor Neuron Disease
- Amyotrophic Lateral Sclerosis
- Molecular Mechanisms of Pharmacological Action
- Membrane Transport Modulators
- Sodium Channel Blockers
- Ranolazine
Other Study ID Numbers
- STUDY00141491
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on ALS
-
Weill Medical College of Cornell UniversityCompleted
-
Beth Israel Deaconess Medical CenterDartmouth-Hitchcock Medical CenterRecruiting
-
Mitsubishi Tanabe Pharma America Inc.CompletedALSUnited States, Canada, Japan, France, Germany, Italy
-
Institut National de la Santé Et de la Recherche...Active, not recruiting
-
Johns Hopkins UniversityUnited States Department of DefenseNot yet recruiting
-
University of PennsylvaniaUniversity of Miami; Biogen; University of KansasTerminated
-
Omar JawdatRare Diseases Clinical Research Network; Terra Biological LLC; Clinical Research...Unknown
-
University of PittsburghALS AssociationCompleted
-
Research Foundation for Mental Hygiene, Inc.Columbia UniversityWithdrawn
Clinical Trials on Ranolazine 500 MG
-
Novartis PharmaceuticalsTerminatedAtherosclerotic Coronary Vascular DiseaseUnited States
-
IRCCS San RaffaeleMenarini International Operations Luxembourg SACompletedHCM - Hypertrophic Non-Obstructive CardiomyopathyItaly
-
Taipei Medical UniversityCompleted
-
Galapagos NVCompleted
-
Spero TherapeuticsRecruitingNontuberculous Mycobacterial Pulmonary Disease (NTM-PD)United States
-
University of Texas Southwestern Medical CenterNational Center for Complementary and Integrative Health (NCCIH)CompletedMajor Depressive DisorderUnited States
-
Loyola UniversityRecruitingOveractive BladderUnited States
-
Lexicon PharmaceuticalsCompletedCarcinoid SyndromeUnited Kingdom
-
Handok Inc.Completed
-
Ultragenyx Pharmaceutical IncCompletedGNE Myopathy | Hereditary Inclusion Body Myopathy (HIBM)United States, Israel